about
Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapyEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.Analysis of ten years of publishing in Pharmacy PracticeRapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study.Network meta-analysis: a technique to gather evidence from direct and indirect comparisonsImpact of Natural Juice Consumption on Plasma Antioxidant Status: A Systematic Review and Meta-Analysis.Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis.Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis.Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis.Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis.Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.Antioxidant effects of vitamins in type 2 diabetes: a meta-analysis of randomized controlled trials.Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysisCost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infectionsDisease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-AnalysisMethodological quality assessment of network meta-analysis of drug interventions: implications from a systematic reviewSafety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)An innovative and comprehensive technique to evaluate different measures of medication adherence: The network meta-analysisEvaluation of the application of the Diabetes Quality of Life Questionnaire in patients with diabetes mellitusMapping pharmacy journals: A lexicographic analysisHaematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysisUsability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventionsThe Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-AnalysisEfficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysisMapping the characteristics of meta-analyses of pharmacy services: a systematic review
P50
Q28078158-744A13A4-7F66-4791-A0D8-D08EDD3468D4Q30240770-06E6F2B8-BF6C-4A2E-ABC1-2FDBF5186013Q36167257-0E0E0E51-A1A5-4A30-83FB-4E59A2C9D6FCQ37532122-6F9589F5-3CCB-4B1C-88DE-9CE28350E885Q37587202-0384DE46-E374-4FE9-95E4-E374CCD668F9Q37745777-B13726A2-F67F-4D06-82E8-BAD71562288FQ38675313-7CBCF4B3-39B5-4E4B-8290-CF0F1B7F6384Q38837174-C9D445F0-F7FD-421E-8021-BC1638DD65DAQ38903835-D8FE3B71-DD1F-479A-A13C-511DD7F84673Q38912639-3EA46FF0-6DFD-4659-844C-07BBE07D8763Q38992214-BD01FE8A-A36C-4398-A4E7-C22EE216DCDDQ39213619-4F2FFA7E-3D1A-460B-B758-91CCB037859EQ39377722-A44C0820-07C8-47EA-924C-BA847ECC8630Q40043040-C1DD4707-0D5C-45F4-9045-258E3AC6F7A4Q42646445-3E6167E5-4286-4330-A0AF-8E4750DAA299Q44823207-5E736ABE-580B-4C9E-9C2C-6ADF8B3D5C8DQ47739367-928F15CF-00C1-46A0-A57F-EFEEFAC7EADBQ48082444-FA534926-D854-4FF2-9DCF-EDED514D2A3AQ49825398-4D15EB94-1856-4249-976A-67A287DCFBA8Q50050582-EC49D261-C8F8-4147-A027-F986051B28B8Q51736297-F206E1FE-BFC4-4681-946E-03422D134949Q57184370-4FDAB0D1-DEDF-4FFE-AEBB-523A221055CBQ57547339-2D09D6B7-23B4-49CC-8559-4601B99C6F6DQ57547346-613EA2C7-70EF-412A-BD51-6585E943AA51Q57547351-1BE9E4E3-1EC7-4B9D-BB1A-1F9648631088Q57547360-73AABB4B-0E4D-429A-9131-D92FD1EA46A5Q57547368-632ED5EB-C798-4384-BC9B-2FD2D93A216EQ90427624-0C64D3DF-E163-4A9D-9C28-A16064E870A8Q91228168-B37CE5FF-C28E-4481-BB7E-232A991CD3CEQ92591474-168D6CD5-B28E-49D3-9499-B49BAB201E30Q92960385-7835B5DC-EEAE-4833-8C53-28D11C127302Q93156286-AA951A58-E55D-4E3A-9384-73821C8FAEF0Q94597421-CACF3EAE-C201-452A-B31C-6630F1E8C369Q95279772-0CBDECCF-B6DF-474B-B215-0F37D9F310D0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fernanda S. Tonin
@ast
Fernanda S. Tonin
@en
Fernanda S. Tonin
@es
Fernanda S. Tonin
@nl
Fernanda S. Tonin
@sl
type
label
Fernanda S. Tonin
@ast
Fernanda S. Tonin
@en
Fernanda S. Tonin
@es
Fernanda S. Tonin
@nl
Fernanda S. Tonin
@sl
altLabel
F Stumpf Tonin
@en
F.S Tonin
@en
F.S. Tonin
@en
Fernanda Stumpf Tonin
@en
prefLabel
Fernanda S. Tonin
@ast
Fernanda S. Tonin
@en
Fernanda S. Tonin
@es
Fernanda S. Tonin
@nl
Fernanda S. Tonin
@sl
P1053
O-2050-2017
P106
P1153
56085115800
P21
P31
P3829
P496
0000-0003-4262-8608